Aptose to Hold KOL Event and Corporate Update Thursday, June

12.05.2022 - Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) ...

Related Keywords

Vienna , Wien , Austria , Aptose Biosciences , Susan Pietropaolo , Rafael Bejar , Lifesci Advisors , Aptose Biosciences Inc , Corporate Communications Investor Relations , Aptose Corporate Update , Webcast Link , Austria June , Acquired Resistance , Acute Myeloid Leukemia Models , Abstract Code , Sci Advisors , Managing Director ,